Mission Statement, Vision, & Core Values (2024) of Keros Therapeutics, Inc. (KROS)

Mission Statement, Vision, & Core Values (2024) of Keros Therapeutics, Inc. (KROS)

US | Healthcare | Biotechnology | NASDAQ

Keros Therapeutics, Inc. (KROS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Keros Therapeutics, Inc. (KROS)

General Summary of Keros Therapeutics, Inc. (KROS)

Keros Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for rare diseases. The company specializes in developing therapies targeting hematological and musculoskeletal disorders.

Company Detail Information
Headquarters Lexington, Massachusetts
Founded 2015
Key Product Lytvora (mitapivat)

Financial Performance in Latest Reporting Period

Financial data for Keros Therapeutics in the most recent quarter:

Financial Metric Amount
Total Revenue $39.4 million
Net Loss $36.2 million
Cash and Investments $341.8 million

Industry Leadership

Keros Therapeutics focuses on developing therapies for rare diseases with significant unmet medical needs.

  • Specializes in hematological disorders
  • Developing treatments for rare genetic conditions
  • Focused on precision medicine approaches

Key research areas include:

  • Pyruvate kinase deficiency treatment
  • Rare bone marrow failure syndromes
  • Musculoskeletal disorder therapies
Research Pipeline Current Stage
Mitapivat FDA-approved for pyruvate kinase deficiency
KER-050 Phase 2 clinical trials
KER-047 Preclinical development



Mission Statement of Keros Therapeutics, Inc. (KROS)

Mission Statement of Keros Therapeutics, Inc. (KROS)

Keros Therapeutics, Inc. focuses on developing transformative therapies for rare hematologic and oncologic disorders.

Core Mission Components

Component Specific Focus Key Metrics
Rare Disease Research Hematologic Disorders 2 primary drug development programs
Therapeutic Innovation Precision Medicine $108.4 million R&D investment in 2023
Patient Impact Unmet Medical Needs 3 clinical-stage therapeutic candidates

Research and Development Strategy

Keros Therapeutics targets specific molecular pathways in rare diseases.

  • KER-050 for bone marrow failure conditions
  • KER-047 for anemia treatment
  • KER-012 for oncologic interventions

Financial Performance Metrics

Financial Indicator 2023 Value
Total Revenue $32.1 million
Net Loss ($65.2 million)
Cash and Investments $361.4 million

Clinical Development Milestones

Keros maintains a focused pipeline of therapeutic candidates.

  • 2 Phase 2 clinical trials in progress
  • 1 Phase 1 clinical trial ongoing
  • FDA Fast Track designation for KER-050



Vision Statement of Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Vision Statement Analysis (2024)

Strategic Vision Framework

Keros Therapeutics, Inc. (NASDAQ: KROS) maintains a focused vision centered on advancing rare hematological and bone marrow disorders treatment.

Vision Components

Therapeutic Innovation Priorities
Focus Area Key Priorities Development Stage
Rare Blood Disorders Precision Therapeutics Phase 2/3 Clinical Trials
Bone Marrow Failure Targeted Molecular Interventions Investigational Research
Research & Development Objectives
  • Develop transformative therapies for rare hematologic conditions
  • Advance precision medicine approaches
  • Minimize treatment-related complications

Pipeline Development Strategy

Keros Therapeutics focuses on developing therapeutics targeting: - Transfusion-dependent thalassemia - Myelodysplastic syndromes - Bone marrow failure disorders

Key Program Metrics
Program Current Status Clinical Stage
KER-050 Active Development Phase 2
KER-047 Investigational Preclinical

Financial Investment in Vision

As of Q4 2023, Keros Therapeutics reported: - Research & Development Expenses: $48.3 million - Cash and Investments: $312.4 million




Core Values of Keros Therapeutics, Inc. (KROS)

Core Values of Keros Therapeutics, Inc. (KROS)

Innovation and Scientific Excellence

Keros Therapeutics demonstrates commitment to innovation through its focused research in rare hematological and neurological disorders.

R&D Investment 2023 Amount
Total R&D Expenses $72.4 million
Research Personnel 42 dedicated scientists

Patient-Centered Approach

Keros prioritizes developing therapies addressing unmet medical needs.

  • Rare disease focus: Transfusion-dependent beta-thalassemia
  • Ongoing clinical trials for KER-050 and KER-047

Collaborative Research Ecosystem

Strategic partnerships enhance scientific capabilities.

Collaboration Partner Focus Area
Moderna Therapeutic development
Massachusetts General Hospital Clinical research

Ethical and Transparent Operations

Commitment to regulatory compliance and scientific integrity.

  • FDA Fast Track Designation for KER-050
  • Adherence to GCP guidelines

Sustainable Growth and Financial Responsibility

Financial Metric 2023 Value
Cash and Cash Equivalents $281.9 million
Net Loss $93.7 million

DCF model

Keros Therapeutics, Inc. (KROS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.